The Inflammatory-Immune Axis in Thyroid Disease: A Mendelian Randomization Study
Tao Pan
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorZhihao Fang
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorTiti Hui
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorXuanlin Wu
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorXu Hu
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorJiabin You
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorCorresponding Author
Chang Liu
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorTao Pan
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorZhihao Fang
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorTiti Hui
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorXuanlin Wu
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorXu Hu
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorJiabin You
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorCorresponding Author
Chang Liu
Department of General Surgery , Fourth Affiliated Hospital of Harbin Medical University , Harbin , China
Search for more papers by this authorAbstract
Background: An increasing body of research has highlighted a close association between circulating inflammatory proteins and thyroid diseases. However, whether this relationship is causal or if immune cells act as intermediaries remains uncertain.
Methods: In this study, we conducted a bidirectional two-sample Mendelian randomization (MR) analysis using data from genome-wide association studies (GWAS) to investigate the potential causal relationships between circulating inflammatory cytokines/proteins, immune cells, and three thyroid diseases: Graves’ disease (GD), Hashimoto’s thyroiditis (HT), and thyroid cancer (TC). We conducted MR analysis using five methods, with the inverse variance-weighted (IVW) approach as the primary method. Sensitivity analyses were performed to assess horizontal pleiotropy and heterogeneity. To enhance result reliability, we applied a False Discovery Rate (FDR) correction to control for multiple testing biases. Lastly, we utilized a two-step MR design to explore the potential mediating role of immune cells in these causal relationships.
Results: Our findings demonstrated a negative association between CCL19 and GD, suggesting that higher levels of CCL19 may be associated with a lower risk of developing GD. Additionally, CCL19 showed a positive correlation with FSC-A on CD4+ T cells, indicating that elevated CCL19 levels are linked to larger cell sizes (FSC-A) in CD4+ T cells. Moreover, FSC-A on CD4+ T cells was inversely associated with GD, suggesting that larger CD4+ T cells (with higher FSC-A) may be linked to a reduced risk of GD. These results indicate that immune cells may act as intermediaries in the pathway involving circulating inflammatory proteins and GD.
Conclusion: The study establishes a causal relationship between circulating inflammatory proteins and immune cells in relation to GD, with immune cells serving as intermediaries in the pathway between inflammatory proteins and GD risk.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
In this study, all data were obtained from publicly available sources, including the IEU Open GWAS project database (https://gwas.mrcieu.ac.uk/), the data.bris Research Data Repository (https://data.bris.ac.uk/data/dataset/3g3i5smgghp0s2uvm1doflkx9x), and the GWAS Catalog (https://www.ebi.ac.uk/gwas/), all of which are freely accessible.
Supporting Information
Filename | Description |
---|---|
ije6644708-sup-0001-f1.xlsxExcel 2007 spreadsheet , 699 KB | Supporting Information 1 STROBE-MR-checklist: Strengthening the Reporting of Observational Studies in Epidemiology-Mendelian Randomization checklist. |
ije6644708-sup-0002-f2.docxWord 2007 document , 410.2 KB | Supporting Information 2 Supporting Figure 1: (A) Leave-one-out sensitivity analyses of MR analyses between CCL19 on GD. (B-K) Leave-one-out sensitivity analyses of MR analyses between circulating immune cells (HLA DR + T cell% lymphocyte, HLA DR + CD4+ %T cell, HLA DR + CD4+ %lymphocyte, FSC−A on CD4+, HLA DR on CD14+ CD16− monocyte, HLA DR on CD14+ monocyte, HLA DR on monocyte, HLA DR on myeloid DC, HLA DR on plasmacytoid DC, HLA DR on DC) on GD. (L) Leave-one-out sensitivity analyses of MR analyses between CCL19 on FSC−A on CD4+. Supporting Figure 2: (A) Funnel plots of MR analyses between CCL19 on GD. (B-K) Funnel plots of MR analyses between circulating immune cells (HLA DR + T cell% lymphocyte, HLA DR + CD4+ %T cell, HLA DR + CD4+ %lymphocyte, FSC−A on CD4+, HLA DR on CD14+ CD16− monocyte, HLA DR on CD14+ monocyte, HLA DR on monocyte, HLA DR on myeloid DC, HLA DR on plasmacytoid DC, HLA DR on DC) on GD. (L) Funnel plots of MR analyses between CCL19 on FSC−A on CD4+. |
ije6644708-sup-0003-f3.docxWord 2007 document , 43.5 KB | Supporting Information 3 Supporting Table 1: The SNPs information for circulating inflammatory cytokines/proteins that exhibit a significant association with thyroid diseases. Supporting Table 2: The SNPs information for immune cells that exhibit a significant association with thyroid diseases. Supporting Table 3: The SNPs information for CCL19 that exhibit a significant association with immune cells. Supporting Table 4: MR estimates for the association between circulating inflammatory cytokines/proteins on thyroid diseases. Supporting Table 5: MR estimates for the association between thyroid diseases on circulating inflammatory cytokines/proteins. Supporting Table 6: MR estimates for the association between 12 immune cells on GD. Supporting Table 7: MR estimates for the association between immune cells on GD. Supporting Table 8: MR estimates for the association between CCL19 on immune cells. Supporting Table 9: The heterogeneity, Horizontal pleiotropy and MR-PRESSO analysis between circulating inflammatory cytokines/proteins on thyroid diseases. Supporting Table 10: The heterogeneity, Horizontal pleiotropy and MR-PRESSO analysis between thyroid diseases on circulating inflammatory cytokines/proteins. Supporting Table 11: The heterogeneity, Horizontal pleiotropy and MR-PRESSO analysis between immune cells on GD. Supporting Table 12: The heterogeneity, Horizontal pleiotropy and MR-PRESSO analysis between CCL19 on immune cells. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Vanderpump M. P., The Epidemiology of Thyroid Disease, British Medical Bulletin. (2011) 99, no. 1, 39–51, https://doi.org/10.1093/bmb/ldr030, 2-s2.0-80052703117.
- 2 Vargas-Uricoechea H., Autoimmune Thyroid Disease and Differentiated Thyroid Carcinoma: A Review of the Mechanisms that Explain an Intriguing and Exciting Relationship, World Journal of Oncology. (2024) 15, no. 1, 14–27, https://doi.org/10.14740/wjon1728.
- 3 Jackson D., Handelsman R. S., Farrá J. C., and Lew J. I., Increased Incidental Thyroid Cancer in Patients With Subclinical Chronic Lymphocytic Thyroiditis, Journal of Surgical Research. (2020) 245, 115–118, https://doi.org/10.1016/j.jss.2019.07.025.
- 4 Antonelli A., Ferrari S. M., Ragusa F. et al., Graves’ Disease: Epidemiology, Genetic and Environmental Risk Factors and Viruses, Best Practice & Research Clinical Endocrinology & Metabolism. (2020) 34, no. 1, https://doi.org/10.1016/j.beem.2020.101387.
- 5 Bartalena L., Diagnosis and Management of Graves Disease: A Global Overview, Nature Reviews Endocrinology. (2013) 9, no. 12, 724–734, https://doi.org/10.1038/nrendo.2013.193, 2-s2.0-84888206548.
- 6 Franklyn J. A. and Boelaert K., Thyrotoxicosis, The Lancet. (2012) 379, no. 9821, 1155–1166, https://doi.org/10.1016/s0140-6736(11)60782-4, 2-s2.0-84859102483.
- 7 Biondi B. and Klein I., Hypothyroidism as a Risk Factor for Cardiovascular Disease, Endocrine. (2004) 24, 001–014, https://doi.org/10.1385/endo:24:1:001.
- 8 Chaker L., Bianco A. C., Jonklaas J., and Peeters R. P., Hypothyroidism, The Lancet. (2017) 390, no. 10101, 1550–1562, https://doi.org/10.1016/s0140-6736(17)30703-1, 2-s2.0-85015741278.
- 9 Wiersinga W. M., Poppe K. G., and Effraimidis G., Hyperthyroidism: Aetiology, Pathogenesis, Diagnosis, Management, Complications, and Prognosis, Lancet Diabetes & Endocrinology. (2023) 11, no. 4, 282–298, https://doi.org/10.1016/s2213-8587(23)00005-0.
- 10 Sung H., Ferlay J., Siegel R. L. et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA: A Cancer Journal for Clinicians. (2021) 71, no. 3, 209–249, https://doi.org/10.3322/caac.21660.
- 11 Antonelli A., Fallahi P., Elia G. et al., Graves’ Disease: Clinical Manifestations, Immune Pathogenesis (Cytokines and Chemokines) and Therapy, Best Practice & Research Clinical Endocrinology & Metabolism. (2020) 34, no. 1, https://doi.org/10.1016/j.beem.2020.101388.
- 12 Phenekos C., Vryonidou A., Gritzapis A. D., Baxevanis C. N., Goula M., and Papamichail M., Th1 and Th2 Serum Cytokine Profiles Characterize Patients with Hashimoto’s thyroiditis (Th1) and Graves’ Disease (Th2), Neuroimmunomodulation. (2004) 11, no. 4, 209–213, https://doi.org/10.1159/000078438, 2-s2.0-3142743942.
- 13 Bartalena L., Piantanida E., Gallo D., Ippolito S., and Tanda M. L., Management of Graves’ Hyperthyroidism: Present and Future, Expert Review of Endocrinology and Metabolism. (2022) 17, no. 2, 153–166, https://doi.org/10.1080/17446651.2022.2052044.
- 14 Ralli M., Angeletti D., Fiore M. et al., Hashimoto’s Thyroiditis: An Update on Pathogenic Mechanisms, Diagnostic Protocols, Therapeutic Strategies, and Potential Malignant Transformation, Autoimmunity Reviews. (2020) 19, no. 10, https://doi.org/10.1016/j.autrev.2020.102649.
- 15 Nabhan F., Dedhia P. H., and Ringel M. D., Thyroid Cancer, Recent Advances in Diagnosis and Therapy, International Journal of Cancer. (2021) 149, no. 5, 984–992, https://doi.org/10.1002/ijc.33690.
- 16 Salvi M., Pedrazzoni M., Girasole G. et al., Serum Concentrations of Proinflammatory Cytokines in Graves’ Disease: Effect of Treatment, Thyroid Function, Ophthalmopathy and Cigarette Smoking, European Journal of Endocrinology. (2000) 143, no. 2, 197–202, https://doi.org/10.1530/eje.0.1430197, 2-s2.0-0033856315.
- 17 Hiratsuka I., Itoh M., Yamada H. et al., Simultaneous Measurement of Serum Chemokines in Autoimmune Thyroid Diseases: Possible Role of IP-10 in the Inflammatory Response, Endocrine Journal. (2015) 62, no. 12, 1059–1066, https://doi.org/10.1507/endocrj.EJ15-0448, 2-s2.0-84952042447.
- 18 Ruffilli I., Ferrari S. M., Colaci M., Ferri C., Fallahi P., and Antonelli A., IP-10 in Autoimmune Thyroiditis, Hormone and Metabolic Research. (2014) 46, no. 09, 597–602, https://doi.org/10.1055/s-0034-1382053, 2-s2.0-84906306942.
- 19 Emdin C. A., Khera A. V., and Kathiresan S., Mendelian Randomization, JAMA. (2017) 318, no. 19, 1925–1926, https://doi.org/10.1001/jama.2017.17219, 2-s2.0-85036533388.
- 20 Skrivankova V. W., Richmond R. C., Woolf B. A. R. et al., Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: the STROBE-MR Statement, JAMA. (2021) 326, no. 16, 1614–1621, https://doi.org/10.1001/jama.2021.18236.
- 21 Orrù V., Steri M., Sidore C. et al., Complex Genetic Signatures in Immune Cells Underlie Autoimmunity and Inform Therapy, Nature Genetics. (2020) 52, no. 10, 1036–1045, https://doi.org/10.1038/s41588-020-0684-4.
- 22 Lin S. H., Brown D. W., and Machiela M. J., LDtrait: An Online Tool for Identifying Published Phenotype Associations in Linkage Disequilibrium, Cancer Research. (2020) 80, no. 16, 3443–3446, https://doi.org/10.1158/0008-5472.Can-20-0985.
- 23 Bowden J., Davey Smith G., and Burgess S., Mendelian Randomization With Invalid Instruments: Effect Estimation and Bias Detection Through Egger Regression, International Journal of Epidemiology. (2015) 44, no. 2, 512–525, https://doi.org/10.1093/ije/dyv080, 2-s2.0-84936755918.
- 24 Bowden J., Davey Smith G., Haycock P. C., and Burgess S., Consistent Estimation in Mendelian Randomization With Some Invalid Instruments Using a Weighted Median Estimator, Genetic Epidemiology. (2016) 40, no. 4, 304–314, https://doi.org/10.1002/gepi.21965, 2-s2.0-84963670568.
- 25 Greco M F. D., Minelli C., Sheehan N. A., and Thompson J. R., Detecting Pleiotropy in Mendelian Randomisation Studies With Summary Data and a Continuous Outcome, Statistics in Medicine. (2015) 34, no. 21, 2926–2940, https://doi.org/10.1002/sim.6522, 2-s2.0-84938292262.
- 26 Verbanck M., Chen C. Y., Neale B., and Do R., Detection of Widespread Horizontal Pleiotropy in Causal Relationships Inferred From Mendelian Randomization Between Complex Traits and Diseases, Nature Genetics. (2018) 50, no. 5, 693–698, https://doi.org/10.1038/s41588-018-0099-7, 2-s2.0-85045854182.
- 27 Hemani G., Zheng J., Elsworth B. et al., The MR-Base Platform Supports Systematic Causal Inference Across the Human Phenome, eLife. (2018) 7, https://doi.org/10.7554/eLife.34408, 2-s2.0-85051679391.
- 28 Hemani G., Tilling K., and Davey Smith G., Orienting the Causal Relationship Between Imprecisely Measured Traits Using GWAS Summary Data, PLoS Genetics. (2017) 13, no. 11, https://doi.org/10.1371/journal.pgen.1007081, 2-s2.0-85036637858.
- 29 Ye X., Chen T., Cheng J. et al., Causal Effects of Circulating Inflammatory Proteins on Oral Phenotypes: Deciphering Immune-Mediated Profiles in the Host-Oral Axis, International Immunopharmacology. (2025) 144, https://doi.org/10.1016/j.intimp.2024.113642.
- 30 Raju R., Gadakh S., Gopal P. et al., Differential Ligand-Signaling Network of CCL19/CCL21-CCR7 System, Database. (2015) 2015, https://doi.org/10.1093/database/bav106, 2-s2.0-84966389729.
- 31 Worbs T., Mempel T. R., Bölter J., von Andrian U. H., and Förster R., CCR7 Ligands Stimulate the Intranodal Motility of T Lymphocytes in Vivo, Journal of Experimental Medicine. (2007) 204, no. 3, 489–495, https://doi.org/10.1084/jem.20061706, 2-s2.0-33947372536.
- 32 Kurobe H., Liu C., Ueno T. et al., CCR7-Dependent Cortex-to-Medulla Migration of Positively Selected Thymocytes is Essential for Establishing Central Tolerance, Immunity. (2006) 24, no. 2, 165–177, https://doi.org/10.1016/j.immuni.2005.12.011, 2-s2.0-32244432265.
- 33 Förster R., Schubel A., Breitfeld D. et al., CCR7 Coordinates the Primary Immune Response by Establishing Functional Microenvironments in Secondary Lymphoid Organs, Cell. (1999) 99, no. 1, 23–33, https://doi.org/10.1016/s0092-8674(00)80059-8, 2-s2.0-0033214348.
- 34 Bromley S. K., Thomas S. Y., and Luster A. D., Chemokine Receptor CCR7 Guides T Cell Exit From Peripheral Tissues and Entry Into Afferent Lymphatics, Nature Immunology. (2005) 6, no. 9, 895–901, https://doi.org/10.1038/ni1240, 2-s2.0-24944583626.
- 35 Yan Y., Chen R., Wang X. et al., CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention, Frontiers in Cell and Developmental Biology. (2019) 7, https://doi.org/10.3389/fcell.2019.00212, 2-s2.0-85073807640.
- 36 Davalos-Misslitz A. M., Rieckenberg J., Willenzon S. et al., Generalized Multi-Organ Autoimmunity in CCR7-Deficient Mice, European Journal of Immunology. (2007) 37, no. 3, 613–622, https://doi.org/10.1002/eji.200636656, 2-s2.0-34147184187.
- 37 Pickens S. R., Chamberlain N. D., Volin M. V., Pope R. M., Mandelin A. M., and Shahrara S., Characterization of CCL19 and CCL21 in Rheumatoid Arthritis, Arthritis & Rheumatism. (2011) 63, no. 4, 914–922, https://doi.org/10.1002/art.30232, 2-s2.0-79953715656.
- 38
Geneva-Popova M. G.,
Popova-Belova S. D.,
Gardzheva P. N., and
Kraev K. I., A Study of IFN-α-Induced Chemokines CCL2, CXCL10 and CCL19 in Patients With Systemic Lupus Erythematosu, The Life. (2022) 12, no. 2, https://doi.org/10.3390/life12020251.
10.3390/life12020251 Google Scholar
- 39 Dhaiban S., Al-Ani M., Elemam N. M., and Maghazachi A. A., Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis, Journal of Inflammation Research. (2020) 13, 619–633, https://doi.org/10.2147/jir.S270872.
- 40 Rump L., Mattey D. L., Kehoe O., and Middleton J., An Initial Investigation Into Endothelial CC Chemokine Expression in the Human Rheumatoid Synovium, Cytokine. (2017) 97, 133–140, https://doi.org/10.1016/j.cyto.2017.05.023, 2-s2.0-85021148298.
- 41 Shi L. J., Li J. H., Hu F. L. et al., Clinical Significance of Serum C-C Chemokine Ligand 19 Levels in Patients With Rheumatoid Arthritis, Beijing Da Xue Xue Bao Yi Xue Ban. (2016) 48, no. 4, 667–671.
- 42 Yang W., Yu T., and Cong Y., CD4(+) T Cell Metabolism, Gut Microbiota, and Autoimmune Diseases: Implication in Precision Medicine of Autoimmune Diseases, Precision Clinical Medicine. (2022) 5, no. 3, https://doi.org/10.1093/pcmedi/pbac018.
- 43 Vom Werth K. L., Kemper B., Kampmeier S., and Mellmann A., Application of Digital Holographic Microscopy to Analyze Changes in T-Cell Morphology in Response to Bacterial Challenge, Cells. (2023) 12, no. 5, https://doi.org/10.3390/cells12050762.
- 44 Lin W., Suo Y., Deng Y. et al., Morphological Change of CD4(+) T Cell During Contact With DC Modulates T-Cell Activation by Accumulation of F-Actin in the Immunology Synapse, BMC Immunology. (2015) 16, no. 1, https://doi.org/10.1186/s12865-015-0108-x, 2-s2.0-84940179018.
- 45 Ploix C., Lo D., and Carson M. J., A Ligand for the Chemokine Receptor CCR7 Can Influence the Homeostatic Proliferation of CD4 T Cells and Progression of Autoimmunity, The Journal of Immunology. (2001) 167, no. 12, 6724–6730, https://doi.org/10.4049/jimmunol.167.12.6724, 2-s2.0-0035892872.
- 46 Campbell J. J., Pan J., and Butcher E. C., Cutting Edge: Developmental Switches in Chemokine Responses During T Cell Maturation, The Journal of Immunology. (1999) 163, no. 5, 2353–2357, https://doi.org/10.4049/jimmunol.163.5.2353.
- 47 Misslitz A., Pabst O., Hintzen G. et al., Thymic T Cell Development and Progenitor Localization Depend on CCR7, Journal of Experimental Medicine. (2004) 200, no. 4, 481–491, https://doi.org/10.1084/jem.20040383, 2-s2.0-4344574151.
- 48 Ye X., Bai Y., Li M. et al., Genetic Associations Between Circulating Immune Cells and Periodontitis Highlight the Prospect of Systemic Immunoregulation in Periodontal Care, eLife. (2024) 12, https://doi.org/10.7554/eLife.92895.